<DOC>
	<DOCNO>NCT00779766</DOCNO>
	<brief_summary>This multicenter study woman plan receive either HPV vaccine control . Study participation last approximately 72 month involve total thirteen fourteen schedule visit . Originally , study plan 24 month . It extend 2 year 4 additional visit ( study end Month 48 ) . The protocol posting update study extend additional 2 year two three additional visit ( study end Month 72 ) subject consent participate extension .</brief_summary>
	<brief_title>Efficacy , Immunogenicity Safety GSK Biologicals ' HPV GSK 580299 Vaccine Healthy Chinese Female Subjects</brief_title>
	<detailed_description>This protocol post update follow protocol amendment 6 date 24 April 2014 .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy Chinese female include 18 25 year age time first vaccination . Subjects investigator believe comply requirement protocol . Written inform consent obtain subject prior enrolment . Healthy subject establish medical history historydirected clinical examination enter study . Subjects must pregnant . Absence pregnancy verify urine pregnancy test . Subjects must nonchildbearing potential , childbearing potential , must abstinent practiced adequate contraception 30 day prior vaccination agree continue precaution 2 month completion vaccination series . Subject must one single intact cervix . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day ( i.e. , Days 029 ) first dose vaccine . Concurrently participate another clinical study , time study period ( Month 24 ) , subject expose investigational noninvestigational product ( pharmaceutical product device ) . A subject planning become pregnant , likely become pregnant ( determined investigator ) planning discontinue contraceptive precaution study period two month last vaccine dose . Pregnant breastfeeding . Subjects must least three month postpregnancy breastfeed enter study . Previous vaccination HPV plan administration HPV vaccine foreseen protocol study period . Previous administration component investigational vaccine . History chronic condition ( ) require treatment cancer autoimmune disease . History allergic disease , suspect allergy reaction likely exacerbate component vaccine . Hypersensitivity latex . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . History colposcopy plan colposcopy evaluate abnormal cervical cytology ( Pap smear ) test .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Human papillomavirus</keyword>
	<keyword>vaccine</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>cervical infection</keyword>
</DOC>